Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering

Documenti analoghi

• Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience
  di: Nihar Desai, et al.
  Pubblicazione: (2024)
• Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation
  di: Nihar Desai, et al.
  Pubblicazione: (2024)
• Lung Biopsies in Patients Referred for Allogeneic Hematopoietic Cell Transplantation: Diagnostic Accuracy, Diagnostic Yield, and Clinical Utility
  di: Sergio Rodriguez‐Rodriguez, et al.
  Pubblicazione: (2026)
• Can we move beyond myeloablative conditioning ( MAC )? A comparison of MAC versus reduced intensity conditioning ( RIC ) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG ‐ PTCy ‐ CSA for GVHD prophylaxis
  di: Ruah Alyamany, et al.
  Pubblicazione: (2025)
• Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based GVHD Prophylaxis
  di: Ahmed Alnughmush, et al.
  Pubblicazione: (2025)